Type 1 Diabetes - Pipeline Insight, 2022
Description
Type 1 Diabetes - Pipeline Insight, 2022
DelveInsight’s, Type 1 Diabetes - Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Type 1 Diabetes: Overview
Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas.
Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells. Insulin is an essential anabolic hormone that exerts multiple effects on glucose, lipid, protein, and mineral metabolism, as well as growth. Importantly, insulin allows glucose to enter muscle and adipose cells, stimulates the liver to store glucose as glycogen and synthesize fatty acids, stimulates the uptake of amino acids, inhibits the breakdown of fat in adipose tissue, and stimulates the uptake of potassium into cells. Individuals with type 1 diabetes mellitus require life-long insulin replacement therapy. Without insulin, diabetic ketoacidosis (DKA) develops and is life-threatening.
The development of T1DM occurs in 3 stages. Stage 1 is asymptomatic and characterized by normal fasting glucose, normal glucose tolerance, and the presence of greater than or equal to 2 pancreatic autoantibodies. Stage 2 diagnostic criteria include the presence of greater than or equal to 2 pancreatic autoantibodies and dysglycemia: impaired fasting glucose (glucose of 100 to 125 mg/dl) or impaired glucose tolerance (2-hour PG of 140 to 199 mg/dL) or a hemoglobin A1c between 5.7% to 6.4%. Individuals remain asymptomatic. In stage 3, there is diabetes or hyperglycemia with clinical symptoms and two or more pancreatic autoantibodies.
""Type 1 Diabetes - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type 1 Diabetes pipeline landscape is provided which includes the disease overview and Type 1 Diabetes treatment guidelines. The assessment part of the report embraces, in depth Type 1 Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 1 Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Teplizumab: Prevention Bio
Teplizumab is an investigational anti-CD3 monoclonal antibody (mAb) being developed for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. In the pivotal TN-10 Study, a single 14-day course of teplizumab delayed insulin-dependent, clinical-stage disease by a median of at least two years in presymptomatic patients with Stage 2 T1D compared to placebo. The observed adverse events were mechanism-based, transient, and predictable, including lymphopenia, transaminase elevations, rash, and cytokine release events.
Emricasan: Histogen
Emricasan is a potential first-in-class, orally active, pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Histogen acquired certain rights to emricasan and other caspase inhibitor compounds as a part of its merger with Conatus Pharmaceuticals Inc. in 2020.
VX-880: Vertex Pharmaceuticals
VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. VX-880 is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection
Further product details are provided in the report……..
Type 1 Diabetes: Therapeutic Assessment
This segment of the report provides insights about the Type 1 Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
Type 1 Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 1 Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 1 Diabetes drugs.
Type 1 Diabetes Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, Type 1 Diabetes - Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Type 1 Diabetes: Overview
Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas.
Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells. Insulin is an essential anabolic hormone that exerts multiple effects on glucose, lipid, protein, and mineral metabolism, as well as growth. Importantly, insulin allows glucose to enter muscle and adipose cells, stimulates the liver to store glucose as glycogen and synthesize fatty acids, stimulates the uptake of amino acids, inhibits the breakdown of fat in adipose tissue, and stimulates the uptake of potassium into cells. Individuals with type 1 diabetes mellitus require life-long insulin replacement therapy. Without insulin, diabetic ketoacidosis (DKA) develops and is life-threatening.
The development of T1DM occurs in 3 stages. Stage 1 is asymptomatic and characterized by normal fasting glucose, normal glucose tolerance, and the presence of greater than or equal to 2 pancreatic autoantibodies. Stage 2 diagnostic criteria include the presence of greater than or equal to 2 pancreatic autoantibodies and dysglycemia: impaired fasting glucose (glucose of 100 to 125 mg/dl) or impaired glucose tolerance (2-hour PG of 140 to 199 mg/dL) or a hemoglobin A1c between 5.7% to 6.4%. Individuals remain asymptomatic. In stage 3, there is diabetes or hyperglycemia with clinical symptoms and two or more pancreatic autoantibodies.
""Type 1 Diabetes - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type 1 Diabetes pipeline landscape is provided which includes the disease overview and Type 1 Diabetes treatment guidelines. The assessment part of the report embraces, in depth Type 1 Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 1 Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Type 1 Diabetes. The therapies under development are focused on novel approaches to treat/improve Type 1 Diabetes.
Teplizumab: Prevention Bio
Teplizumab is an investigational anti-CD3 monoclonal antibody (mAb) being developed for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. In the pivotal TN-10 Study, a single 14-day course of teplizumab delayed insulin-dependent, clinical-stage disease by a median of at least two years in presymptomatic patients with Stage 2 T1D compared to placebo. The observed adverse events were mechanism-based, transient, and predictable, including lymphopenia, transaminase elevations, rash, and cytokine release events.
Emricasan: Histogen
Emricasan is a potential first-in-class, orally active, pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Histogen acquired certain rights to emricasan and other caspase inhibitor compounds as a part of its merger with Conatus Pharmaceuticals Inc. in 2020.
VX-880: Vertex Pharmaceuticals
VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. VX-880 is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection
Further product details are provided in the report……..
Type 1 Diabetes: Therapeutic Assessment
This segment of the report provides insights about the Type 1 Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Type 1 Diabetes
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Type 1 Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 1 Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 1 Diabetes drugs.
Type 1 Diabetes Report Insights
- Type 1 Diabetes Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Type 1 Diabetes drugs?
- How many Type 1 Diabetes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type 1 Diabetes?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type 1 Diabetes therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Type 1 Diabetes and their status?
- What are the key designations that have been granted to the emerging drugs?
- Landos Biopharma
- Diamyd Medical
- Gan&Lee Pharmaceuticals
- Zealand Pharma
- Kamada
- AstraZeneca
- Novo Nordisk
- Provention Bio
- Histogen
- Vertex Pharmaceuticals
- Panbela Therapeutics
- Arecor
- Bioprojet
- Novartis
- ImCyse
- Adocia
- Anelixis Therapeutics
- Tolerion
- TikoMed
- Avotres
- REMD Biotherapeutics
- Novo Nordisk
- LABP 111
- Autoimmune diabetes vaccine
- Insulin lispro biosimilar
- Dasiglucagon
- Alpha-1 antitrypsin
- Exenatide
- Dextran sulfate-low molecular weight
- TTP 399
- Teplizumab
- Emricasan
- VX 880
- Eflornithine oral
- Ultra-rapid acting insulin aspart
- Pitolisant
- Iscalimab
- IMCY 0098
- Insulin/pramlintide
- AT-1501
- TOL 3021
- AVT001
- Volagidemab
- NNC0363 0845
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
220 Pages
- Introduction
- Executive Summary
- Type 1 Diabetes: Overview
- What is Type 1 Diabetes?
- Types of Type 1 Diabetes
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Type 1 Diabetes– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- Teplizumab: Provention Bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- TTP 399: Novo Nordisk
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- SBP 101: Takeda Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Eflornithine oral: Panbela Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Type 1 Diabetes Key Companies
- Type 1 Diabetes Key Products
- Type 1 Diabetes- Unmet Needs
- Type 1 Diabetes- Market Drivers and Barriers
- Type 1 Diabetes- Future Perspectives and Conclusion
- Type 1 Diabetes Analyst Views
- Type 1 Diabetes Key Companies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
